Pliant Therapeutics, Inc. (PLRX)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
PLRX Annual Report Filing Requires Full Content Upload to Proceed
I am ready to act as your expert financial analyst and educator! However, the document you provided appears to be a placeholder or a corrupted link. While the system metadata confirms the document is an Annual Report (ARS) for PLIANT THERAPEUTICS, INC., there is no readable text or PDF content attac
SEC filings
All filings →Insider trades
All insider trades →Pliant Therapeutics, Inc. has no reported insider trades in the last 90 days.